FDA Rejects Rivaroxaban for ACS
Following a close vote, a U.S. Food and Drug Administration panel has declined to recommend r ivaroxaban ( Xarelto ) to treat acute coronary syndrome.
Risk High During Temporary Anticoagulant Halts
Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.
Rivaroxaban for Treating Pulmonary Embolism
New oral blood thinner rivaroxaban ( Xarelto ) has been shown to be safer for treating a pulmonary embolism as compared to enoxaparin ( Lovenox ) injections, and was found to be just as effective.